drugset / Trial / NCT07550972

Neoadjuvant Treatment of Locally Advanced HNSCC With Pertuzumab Combined With Lenvatinib.

NCT07550972

Phase 2 Enrolling by invitation 30 enrolled Zhejiang Provincial People's Hospital
NaSingle-groupOpen-labelTreatment

Summary

A single-arm, single-center clinical trial evaluating efficacy (Phase #)

Timeline

Start
2026-05-01
Primary completion
2030-03-31
Completion
2030-03-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Lenvatinib Small molecule 8 mg
Comparator Pertuzumab Monoclonal antibody 3 mg/kg